The third-year results of denosumab sequential therapy trial: An extension of a randomized clinical trial.
BACKGROUND/PURPOSE Denosumab effectively increases bone mineral density (BMD) and reduces fracture risk in osteoporosis patients. Denosumab discontinuation is related with rebound bone loss and increased fracture risk. Zoledronate has been proposed as sequential therapy to mitigate this effect. We investigated the effi...